GLP-1 Market Size, Share & Trends Analysis Report By Type of GLP-1 Agonist Drugs (Long-acting GLP-1 Agonist, Short-acting GLP-1 Agonist), By Type of Agonist (Single Agonist, Dual Agonist, Tri-agonist), By Molecule Type (Biologic Peptide GLP-1 Agonists, Small-Molecule Non-Peptide GLP-1 Agonists), By Active Compound (Semaglutide, Tirzepatide, Dulaglutide, Liraglutide, Lixisenatide, Exenatide, Orforglipron, Retatrutide, Survodutide, Other Active Compounds), By Route of Administration (Oral, Parenteral), By Dosing Frequency (Daily, Weekly, Monthly or Extended-Interval), By Delivery System, By Target Indication, By Payer, By Region and By Segments Forecasts, 2026 to 2035
People forget to drink, Wojeck says
After all, maintaining a balanced diet is key to long-term success and overall well-being
Heart health (Major Adverse Cardiovascular Events MACE) early evidence suggests a possible cardiovascular benefit, with a large dedicated outcomes trial underway to confirm this (JAMA Network Open, 2024)
However, the changes in the gut microbiota were not completely consistent among these studies
Kimberly Gudzune, the medical director for the American Board of Obesity Medicine who treats people with obesity and diabetes at Johns Hopkins, said her practice has been getting so many new requests for time-intensive prior authorizations from insurance companies that it had to hire an additional staff member to help
)
